Drug intelligence / Profile preview

DynaGraft II

Development stage: Unknown
Lead developer: IsoTis
Modality: Device-based Delivery → Drug Delivery Systems
Administration: Implant

Overview

DynaGraft II is a bone graft substitute medical device composed of demineralized bone matrix (DBM) derived from donated human bone tissue, combined with a poloxamer-based reverse phase carrier medium. Developed by IsoTis OrthoBiologics (later acquired by Integra LifeSciences), it received FDA 510(k) clearance in 2005 for use in orthopedic and dental applications. The product is designed as a bone void filler that provides osteoinductive potential to stimulate new bone formation. Its unique reverse phase medium allows the material to be malleable at room temperature but thicken at body temperature, which helps contain the graft material at the surgical site during bone grafting procedures.

Brand names: DynaGraft II

Beyond the preview

Go deeper on DynaGraft II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DynaGraft II.

Explore the full profile